• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Regeneron Pharmaceuticals (NQ:REGN)

    656.01 +4.10 (+0.63%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Jul 24, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 708,393
    Open 658.29
    Bid (Size) 645.49 (40)
    Ask (Size) 668.69 (40)
    Prev. Close 651.91
    Today's Range 654.05 - 667.50
    52wk Range 541.00 - 821.11
    Shares Outstanding 91,779,465
    Dividend Yield 0.57%
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    REGN Investors Have Opportunity to Lead Regeneron Pharmaceuticals, Inc. Securities Fraud Lawsuit with the Schall Law Firm
    From Schall Law
    Via GlobeNewswire
    Regeneron Pharmaceuticals (NASDAQ:REGN): A Quality Value Stock with Decent Growth and a Clear Discount ↗
    Via Chartmill

    Performance

    YTD
    -15.5%
    -15.5%
    1 Month
    +5.2%
    +5.2%
    3 Month
    -12.7%
    -12.7%
    6 Month
    -12.9%
    -12.9%
    1 Year
    +16.2%
    +16.2%

    More News

    Read More
    News headline image
    REGN Shareholder Alert: Regeneron Pharmaceuticals, Inc. Securities Class Action Lawsuit - Investors With Losses May Contact Levi & Korsinsky
    From Levi & Korsinsky, LLP
    Via Business Wire
    News headline image
    Did You Lose Money Investing in Regeneron Pharmaceuticals, Inc.? Robbins LLP Urges Investors with Significant Losses to Contact the Firm for Information About Their Rights Against REGN
    Via Newsfile
    Topics Earnings
    News headline image
    SHAREHOLDER ALERT Bernstein Liebhard LLP Announces a Securities Fraud Class Action Lawsuit Has Been Filed Against Regeneron Pharmaceuticals, Inc. (REGN)
    From Bernstein Liebhard LLP
    Via GlobeNewswire
    News headline image
    REGN INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds Regeneron Investors of Securities Class Action Lawsuit Deadline on September 14, 2026
    From Faruqi & Faruqi, LLP
    Via Business Wire
    News headline image
    REGENERNON PHARMACEUTICALS, INC. INVESTORS WITH LOSSES HAVE UNTIL SEPTEMBER 14, 2026 TO JOIN SECURITIES CLASS ACTION – Bernstein Liebhard LLP Announces Deadline
    From Bernstein Liebhard LLP
    Via GlobeNewswire
    News headline image
    REGN Breaking News: Regeneron Inc. Sued for Securities Fraud after Revealing Failed Phase III Clinical Trial Resulting in 10% Stock Drop – Investors Notified to Contact BFA Law
    From Bleichmar Fonti & Auld LLP
    Via Business Wire
    News headline image
    INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Regeneron Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines – REGN
    From Pomerantz LLP
    Via GlobeNewswire
    News headline image
    REGN Investors Have Opportunity to Lead Regeneron Pharmaceuticals, Inc. Securities Fraud Lawsuit with the Schall Law Firm
    From Schall Law
    Via GlobeNewswire
    News headline image
    REGENERNON PHARMACEUTICALS, INC. (REGN) INVESTOR ALERT Investors With Large Losses in Regeneron Pharmaceuticals, Inc. Should Contact Bernstein Liebhard LLP To Discuss Their Rights
    From Bernstein Liebhard LLP
    Via GlobeNewswire
    News headline image
    Regeneron Pharmaceuticals, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights – REGN
    From DJS Law Group
    Via Business Wire
    News headline image
    REGN Investors Have Opportunity to Lead Regeneron Pharmaceuticals, Inc. Securities Fraud Lawsuit with the Schall Law Firm
    From The Schall Law Firm
    Via Business Wire
    News headline image
    REGENERON ALERT: Bragar Eagel & Squire, P.C. is Investigating Regeneron Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
    From Bragar Eagel & Squire
    Via GlobeNewswire
    News headline image
    REGN DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Regeneron Investors of Securities Class Action Lawsuit Deadline on September 14, 2026
    From Faruqi & Faruqi LLP
    Via GlobeNewswire
    News headline image
    3 High-Yield Dividend Stocks to Buy and Hold ↗
    Via The Motley Fool
    Topics Intellectual Property
    News headline image
    Investor Notice: Robbins LLP Informs Investors of the Regeneron Pharmaceuticals, Inc. Class Action Lawsuit
    From Robbins LLP
    Via Business Wire
    News headline image
    1 Large-Cap Stock with Exciting Potential and 2 We Turn Down
    Via StockStory
    News headline image
    Wall Street Thinks This Biotech Stock Can Soar 45%. Here's Why Analysts Are Right. ↗
    Via The Motley Fool
    News headline image
    Wall Street Thinks This High-Flying Biotech Stock Can Soar Another 57% ↗
    Via The Motley Fool
    Hormuz Goes Quiet, Software Wakes Up, and Burry Picks a Side ↗
    Via Chartmill
    News headline image
    Will SpaceX Stock Double Anytime Soon? No -- but These 3 Stocks Could ↗
    Via The Motley Fool
    News headline image
    This Little-Known Biotech Just Delivered a Bigger IPO Pop Than SpaceX -- and Regeneron Is Already Invested ↗
    Via The Motley Fool
    Topics Initial Public Offering
    News headline image
    Regeneron to Report Second Quarter 2026 Financial and Operating Results and Host Conference Call and Webcast
    From Regeneron Pharmaceuticals, Inc.
    Via GlobeNewswire
    News headline image
    2 Underrated Weight Loss Stocks to Buy and Hold ↗
    Via The Motley Fool

    Frequently Asked Questions

    Is Regeneron Pharmaceuticals publicly traded?
    Yes, Regeneron Pharmaceuticals is publicly traded.
    What exchange does Regeneron Pharmaceuticals trade on?
    Regeneron Pharmaceuticals trades on the Nasdaq Stock Market
    What is the ticker symbol for Regeneron Pharmaceuticals?
    The ticker symbol for Regeneron Pharmaceuticals is REGN on the Nasdaq Stock Market
    What is the current price of Regeneron Pharmaceuticals?
    The current price of Regeneron Pharmaceuticals is 656.01
    When was Regeneron Pharmaceuticals last traded?
    The last trade of Regeneron Pharmaceuticals was at 07/24/26 04:00 PM ET
    What is the market capitalization of Regeneron Pharmaceuticals?
    The market capitalization of Regeneron Pharmaceuticals is 60.21B
    How many shares of Regeneron Pharmaceuticals are outstanding?
    Regeneron Pharmaceuticals has 60B shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.